Cocrystal Pharma, Inc. announced a registered direct offering priced at-the-market under Nasdaq rules.
The offering includes the purchase and sale of 2,764,710 shares of common stock at $1.70 per share with potential additional proceeds from warrants.
The Company intends to use the net proceeds for working capital and general corporate purposes.
Offering Details
2,764,710 shares of common stock priced at $1.70 per share with additional potential gross proceeds from warrants.
Placement Agent
H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Net Proceeds
Expected gross proceeds to be approximately $4.7 million with additional potential gross proceeds of $8.3 million from fully-exercised warrants.
- The offering aims to raise funds for working capital and general corporate purposes, indicating strategic financial planning by the Company.
- The involvement of H.C. Wainwright & Co. as the placement agent highlights the Company's collaboration with reputable financial entities.
Cocrystal Pharma, Inc.'s registered direct offering signifies a proactive approach to securing funds for operational needs, demonstrating a commitment to financial stability and growth.